TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Smith, 2014, Declining childhood and adolescent cancer mortality, Cancer, 120, 2497, 10.1002/cncr.28748 Leddon, 2015, Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity, Mol Ther Oncolytics, 1, 14010, 10.1038/mto.2014.10 Currier, 2005, Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses, Cancer Gene Ther., 12, 407, 10.1038/sj.cgt.7700799 Eshun, 2010, VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy, Gene Ther., 17, 922, 10.1038/gt.2010.82 Currier, 2008, Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide, Mol. Ther., 16, 879, 10.1038/mt.2008.49 Chen, 2017, Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models, Sci. Rep., 7, 2396, 10.1038/s41598-017-02503-8 Saha, 2016, Oncolytic herpes simplex virus interactions with the host immune system, Curr. Opin. Virol., 21, 26, 10.1016/j.coviro.2016.07.007 Keller, 2016, Oncolytic viruses-immunotherapeutics on the rise, J. Mol. Med. (Berl.), 94, 979, 10.1007/s00109-016-1453-9 Andtbacka, 2016, Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial, Ann. Surg. Oncol., 23, 4169, 10.1245/s10434-016-5286-0 Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J. Clin. Oncol., 33, 2780, 10.1200/JCO.2014.58.3377 Rajani, 2015, Harnessing the power of onco-immunotherapy with checkpoint inhibitors, Viruses, 7, 5889, 10.3390/v7112914 Woller, 2015, Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses, Mol. Ther., 23, 1630, 10.1038/mt.2015.115 Cassady, 2016, To Infection and beyond: the multi-pronged anti-cancer mechanisms of oncolytic viruses, Viruses, 8, 8, 10.3390/v8020043 Puzanov, 2016, Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma, J. Clin. Oncol., 34, 2619, 10.1200/JCO.2016.67.1529 Akhurst, 2012, Targeting the TGFβ signalling pathway in disease, Nat. Rev. Drug Discov., 11, 790, 10.1038/nrd3810 Yoshimura, 2011, TGF-β function in immune suppression, Curr. Top. Microbiol. Immunol., 350, 127 Pickup, 2013, The roles of TGFβ in the tumour microenvironment, Nat. Rev. Cancer, 13, 788, 10.1038/nrc3603 Padua, 2009, Roles of TGFbeta in metastasis, Cell Res., 19, 89, 10.1038/cr.2008.316 Bouché, 2000, TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells, FASEB J., 14, 1147, 10.1096/fasebj.14.9.1147 Wang, 2010, TGF-beta1 signal pathway may contribute to rhabdomyosarcoma development by inhibiting differentiation, Cancer Sci., 101, 1108, 10.1111/j.1349-7006.2010.01512.x Neuzillet, 2015, Targeting the TGFβ pathway for cancer therapy, Pharmacol. Ther., 147, 22, 10.1016/j.pharmthera.2014.11.001 Tojo, 2005, The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta, Cancer Sci., 96, 791, 10.1111/j.1349-7006.2005.00103.x MacKie, 2001, Intralesional injection of herpes simplex virus 1716 in metastatic melanoma, Lancet, 357, 525, 10.1016/S0140-6736(00)04048-4 Cripe, T. (2009). HSV1716 in patients with non-central nervous system (non-CNS) solid tumors. Report of the U.S. National Institutes of Health. May 2009, NCT00931931. http://clinicaltrials.gov/show/NCT00931931. Streby, 2017, Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients, Clin. Cancer Res., 23, 3566, 10.1158/1078-0432.CCR-16-2900 Benencia, 2005, HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer, Mol. Ther., 12, 789, 10.1016/j.ymthe.2005.03.026 Benencia, 2008, Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation, Cancer Biol. Ther., 7, 1194, 10.4161/cbt.7.8.6216 Meadors, 2011, Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy, Pediatr. Blood Cancer, 57, 921, 10.1002/pbc.23048 Mandl, 2012, Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells, Cancer Immunol. Immunother., 61, 19, 10.1007/s00262-011-1077-4 Han, 2015, TGFβ treatment enhances glioblastoma virotherapy by inhibiting the innate immune response, Cancer Res., 75, 5273, 10.1158/0008-5472.CAN-15-0894 Ilkow, 2015, Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity, Nat. Med., 21, 530, 10.1038/nm.3848 Yoneyama, 2004, The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses, Nat. Immunol., 5, 730, 10.1038/ni1087 Hu, 2010, Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model, Hum. Gene Ther., 21, 1623, 10.1089/hum.2010.018 Hu, 2012, Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model, Hum. Gene Ther., 23, 871, 10.1089/hum.2012.040 Zhang, 2012, Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host, Cancer Gene Ther., 19, 630, 10.1038/cgt.2012.41 Thomas, 2005, TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, 8, 369, 10.1016/j.ccr.2005.10.012 Wan, 2007, ‘Yin-Yang’ functions of transforming growth factor-beta and T regulatory cells in immune regulation, Immunol. Rev., 220, 199, 10.1111/j.1600-065X.2007.00565.x